Michael D Hogarty

List of Publications by Year
in descending order

88	8,293	87888 38	56724 83
papers	citations	h-index	g-index

94	94	94	9606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuroblastoma. Lancet, The, 2007, 369, 2106-2120.	13.7	1,856
2	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	21.4	990
3	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
4	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics, 2013, 45, 12-17.	21.4	374
5	ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell, 2012, 22, 631-644.	16.8	309
6	ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. Cancer Cell, 2014, 26, 682-694.	16.8	302
7	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 985-993.	1.5	285
8	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-4957.	5.9	228
9	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	7.4	220
10	ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma. Cancer Research, 2008, 68, 9735-9745.	0.9	200
11	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
12	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
13	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene, 2005, 24, 2684-2694.	5.9	147
14	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	1.6	146
15	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine, 2019, 11, .	12.4	99
16	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
17	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
18	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature Communications, 2021, 12, 511.	12.8	85

#	Article	IF	Citations
19	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget, 2016, 7, 21840-21852.	1.8	85
20	Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 5725-5734.	1.6	84
21	Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biology and Therapy, 2009, 8, 1587-1595.	3.4	80
22	Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Letters, 2005, 228, 133-141.	7.2	79
23	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
24	The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737. Journal of Biological Chemistry, 2013, 288, 6980-6990.	3.4	67
25	MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913.	12.8	66
26	Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma. Cancer Research, 2012, 72, 2565-2577.	0.9	65
27	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 32-36.	1.0	63
28	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Translational Pediatrics, 2015, 4, 226-38.	1.2	63
29	Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clinical Cancer Research, 2016, 22, 4391-4404.	7.0	61
30	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
31	The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Letters, 2003, 197, 173-179.	7.2	58
32	Inhibition of the oncogenic fusion protein EWS-FLI1 causes G ₂ -M cell cycle arrest and enhanced vincristine sensitivity in Ewingâ€™s sarcoma. Science Signaling, 2017, 10, .	3.6	51
33	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 24-27.	1.0	48
34	Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma. Clinical Cancer Research, 2009, 15, 5956-5961.	7.0	46
35	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports, 2018, 25, 1255-1267.e5.	6.4	46
36	Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research, 2003, 9, 3345-55.	7.0	46

#	Article	IF	Citations
37	TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Letters, 2015, 357, 412-418.	7.2	44
38	Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Frontiers in Oncology, 2012, 2, 162.	2.8	43
39	The challenge of defining â€œultraâ€highâ€riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
40	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
41	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	1.6	41
42	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet Child and Adolescent Health, 2018, 2, 25-34.	5.6	38
43	Deletion of 11q23 is a frequent event in the evolution ofMYCN single-copy high-risk neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 544-546.	1.0	37
44	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	31
45	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
46	Mutations in PIK3CAare infrequent in neuroblastoma. BMC Cancer, 2006, 6, 177.	2.6	29
47	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with highâ€risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	1.5	29
48	Myc, Oncogenic Protein Translation, and the Role of Polyamines. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 Td	2.9	28
49	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
50	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
51	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 2015, 6, 18558-18576.	1.8	26
52	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
53	A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma. Oncotarget, 2016, 7, 49246-49258.	1.8	25
54	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia, 2019, 33, 2429-2441.	7.2	24

#	Article	IF	Citations
55	BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines withMYCN amplification. Medical and Pediatric Oncology, 2000, 35, 559-562.	1.0	21
56	Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS ONE, 2016, 11, e0161039.	2.5	21
57	Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	21
58	EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma. Cancer Biology and Therapy, 2015, 16, 276-286.	3.4	20
59	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	2.1	20
60	Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. Frontiers in Immunology, 2020, 11, 873.	4.8	20
61	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Childrenâ€™s Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 474-481.	6.4	19
62	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	4.8	18
63	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	17
64	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 52-55.	1.0	16
65	PI3King on MYCN to Improve Neuroblastoma Therapeutics. Cancer Cell, 2012, 21, 145-147.	16.8	16
66	Reduced ERâ€“mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO Journal, 2022, 41, e108272.	7.8	16
67	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	1.2	14
68	IL-17A in LCH: Systemic Biomarker, Local Factor, or None of the Above?. Molecular Therapy, 2011, 19, 1405-1406.	8.2	10
69	Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency. Pediatric Research, 2020, 88, 163-167.	2.3	10
70	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	3.7	10
71	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
72	BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatric Blood and Cancer, 2021, 68, e28933.	1.5	9

#	Article	IF	Citations
73	No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3. Cancer Research, 2002, 62, 6481-4.	0.9	8
74	Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein. Cell Research, 2010, 20, 391-393.	12.0	7
75	MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. Scientific Reports, 2021, 11, 14454.	3.3	6
76	Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours. International Journal of Oncology, 2018, 52, 967-977.	3.3	4
77	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
78	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
79	NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.. Journal of Clinical Oncology, 2018, 36, 10558-10558.	1.6	3
80	Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10525-10525.	1.6	2
81	Expanding MYCN's Reach in Oncogenic Transcription. Journal of the National Cancer Institute, 2015, 107, djv122-djv122.	6.3	1
82	Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.. Journal of Clinical Oncology, 2016, 34, e14014-e14014.	1.6	1
83	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
84	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	1.6	0
85	The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur. Pediatric Blood and Cancer, 2020, 67, e28191.	1.5	0
86	Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas. , 2015, , .		0
87	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients â‰¥18 months with unfavorable histology and without MYCN amplification: A Childrenâ€™s Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10502-10502.	1.6	0
88	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Childrenâ€™s Oncology Group (COG) risk stratification.. Journal of Clinical Oncology, 2022, 40, 10013-10013.	1.6	0